

a/

-- 16. The method according to claim 2 characterized in that the DNA vector is a plasmid containing the luxCDABE genes (SEQ ID NO:3), tetracycline repressor (TetR) (SEQ ID NO:11) and tetracycline promotor (TetA) (SEQ ID NO:9) from *Tn*10. --

-- 17. The method according to claim 16 characterized in that the DNA vector is the plasmid pTetLux1 (SEQ ID NO:3). --

-- 18. The method according to claim 2 characterized in that

- the DNA vector is a plasmid containing the insect luciferase gene (SEQ ID NO:1), tetracycline repressor (TetR) (SEQ ID NO:11) and tetracycline promoter (TetA) (SEQ ID NO:9) from *Tn*10, and that
- D-luciferin is added to the mixture of the sample and the cells in order to initiate the luminescence of the cells. --

-- 19. The method according to claim 18 characterized in that the DNA vector is the plasmid pTetLuc1 (SEQ ID NO:1). --

-- 20. The cell according to claim 12 characterized in that it is in dried form, e.g., in lyophilized form. --

REMARKS

The claims have been amended to delete multiple dependencies and to bring them more into conformance with U.S. practice. No new matter has been added by the above amendments, and their entry is therefore requested.

Respectfully submitted,

By

Jeffrey L. Ihnen
Jeffrey L. Ihnen, Reg. No. 28,957
Attorney for Applicants
ROTHWELL, FIGG, ERNST & KURZ, p.c.
Suite 701-E, 555 13th Street, N.W.
Washington, D.C. 20004
Telephone: (202)783-6040

Dated: 24 April 2000